TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
1. Inclusion Criteria for relapse Group :~   * Children aged from 1 to 18 years at the time of first B-ALL relapse diagnosis~  * Obtention of oral and written consent of the parents~  * Parents affiliated with the social security system~2. Inclusion Criteria for control Group :~   * Children aged from 1 to 18 years enrolled into FRALLE or EORTC treatment protocols, treated for B-ALL and who are in complete molecular remission~  * Obtention of oral and written consent of the parents~  * Parents affiliated with the social security system~3. Exclusion criteria for control Group are the same as for relapsed Group :~   * Children with hematologic syndrome predisposing to hematologic neoplasia (such as Fanconi's anaemia, Diamond Blackfan anaemia ...) or acute leukemia secondary to previous treatment, or who have had allogenic hematopoietic stem cell transplantation before relapse

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Relapse Group (Type: OTHER): * Collection of blood samples will be done in newly diagnosed relapse of B-ALL children at the time of relapse diagnosis.~* Children aged from 1 to 18 years at the time of first B-ALL relapse diagnosis.
- Control Group (Type: OTHER): * Collection of blood samples will be done at the same stage of treatment as the relapse group has been collected.~* Children aged from 1 to 18 years enrolled into FRALLE (protocol of treatment) or EORTC (European Organisation for Research and Treatment of Cancer) treatment protocols, treated for B-ALL and who are in complete molecular remission.~* These control patients will be recruited at the same time from the beginning of B-ALL treatment as paired-relapsed control patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Quality of Life in Barrett's Esophagus and Gastro-Esophageal Reflux Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Age 18 or above~At least one of the following:~Previous diagnosis of Barrett's esophagus Presence of GERD symptoms per patient report~Exclusion Criteria:~None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- No Barrett's esophagus (Type: None): Subject without columnar lined esophagus
- Nondysplastic BE (Type: None): Subject with columnar lined esophagus and absence of dysplasia
- Low grade dysplastic BE (Type: None): subject with columnar lined esophagus and presence of low grade dysplasia
- High grade dysplastic BE (Type: None): subject with columnar lined esophagus and presence of high grade dysplasia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Proton Beam Radiation Therapy for Intraocular and Periocular Retinoblastoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Active or recurrent retinoblastoma patient eligible for treatment of external beam radiation therapy.~2. A parent or guardian who can provide informed consent to a minor or child participant.~3. No concurrent infection.~4. No contraindication for repeated general anesthesia/sedation.~Exclusion Criteria:~1. Inability to return for multiple examinations under anesthesia.~2. Medical contraindication for exams under anesthesia/sedation.~3. Unreliable follow-up.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Proton Beam Radiation Therapy (Type: EXPERIMENTAL): Radiation given daily for 5 days in a row each week (except for Saturdays, Sundays, and holidays). The whole treatment will take about 4-6 weeks. Ophthalmic examination under anesthesia including dilated eye exam, ocular fundus photography (Ret-Cam), ocular echography and neuro-radiologic assessment (as deemed necessary)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Remote Monitoring in Obstructive Sleep Apnea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed OSA patients~* AHI of 5/hour or greater~* Prescribed CPAP therapy~* Able to comply with treatment and understand treatment instructions~Exclusion Criteria:~* Not able to understand study requirements~* Significant cardiorespiratory disease - e.g. COPD (chronic obstructive pulmonary disease), severe CHF (congestive heart failure)~* Clinical instability at time of apnea diagnosis~* Prescribed BiPap (bilevel positive airway pressure) or ASV (Adaptive Support Ventilation), which are other types of PAP

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Usual Care (Type: ACTIVE_COMPARATOR): Monitoring every 3 months by face-to-face visits:These patients will be monitored on a 3-month, 6-month, 9-month and 12-month intervals with scheduling face-to-face visits. Adherence and efficacy data will only be assessed by the clinician at these intervals.
- Wireless Care (Type: ACTIVE_COMPARATOR): Frequent remote monitoring:These patients will be monitored using wireless modems as the method to obtain adherence and efficacy data.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Nephrotoxicity Associated to Parenchymal Clamping During Partial Nephrectomy Using a Microdialysis Technique

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients referred to the urological surgery department with an indication of partial nephrectomy~* Patients with a renal lesion classified T1 (≤7cm) or for T2 eligible to a partial nephrectomy and having an possibility to benefit from a parenchymal clamping (decided on preoperative imaging)~Exclusion Criteria:~* Patient with a chronic kidney disease (functional or structural renal abnormality evolving for more than three months and Glomerular Filtration Rate \<60 ml/min)~* Patient carrying a renal lesion classified T1 but too close to the renal pedicle or not accessible for a parenchymal clamping~* Patients in whom tumor removal requires ice cooling or kidney pedicular clamping

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- renal microdialysis (Type: OTHER): patient with renal microdialysis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: FSU Hypertension Self-Care Training Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of hypertension~* Age 25 or older~Exclusion Criteria:~* Pregnancy~* Participation in other clinical trials or drug/behavioral treatment~* Previously participated in any other clinical trials/training on health-related behavior (tai-chi, yoga, nutritional education, yoga class)~* Kidney disease~* Cancer/chemotherapy, advanced HIV/AIDS, severe liver disease~* Severe ischemic heart disease (unstable angina, hospitalization for heart attack, coronary revascularization)~* Congestive heart failure~* Severe inflammatory/rheumatologic disorders (severe arthritis)~* Severe mental health diagnosis such as schizophrenia or bi-polar disorder~* Occurrence of any neurological disorders such as stroke or dementia~* Addicted to any legal/illegal drugs or alcohol without at least 1 year of sobriety~* Any infectious conditions such as pneumonia, traumatic wound, or surgery that may cause inflammation in the past 14 days

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enhancing willpower using active skills (Type: EXPERIMENTAL): This group will use active tasks such as learning skills using hands to enhance willpower.
- Enhancing willpower using passive tasks (Type: EXPERIMENTAL): This group will use passive tasks such as taking still postures to enhance willpower.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Eclampsia and Posterior Reversible Encephalopathy Syndrome (PRES):

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Currently 34 weeks pregnant or within 6 weeks postpartum~2. At least 18 years of age~3. Singleton or twin gestation~4. Patient or family sign informed consent~5. Diagnosis of eclampsia~6. Able to obtain MRI scanning within 24hours of hosp admit and/or seizure~Exclusion Criteria:~1. Neither pregnant nor within first 6 weeks postpartum~2. Patient or family unable to sign informed consent~3. Less than 18 years of age~4. Triplet or higher order gestation~5. Unable to obtain MRI scanning within 24 hours of hospital admission (~6. Diagnosis of cerebral hemorrhage~7. Patient in whom MRI is contraindicated

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Dexamethasone (Type: ACTIVE_COMPARATOR): Dexamethasone 12 mg, 2 doses, 12 hours apart.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, 2 doses, 12 hours apart

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Observational Study Investigating Clinical & Anthropometric Characteristics of Children With Achondroplasia.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent is obtained from the children's parent(s) / legal guardian(s) before any study-related activity is carried out~2. The child is able to provide written informed assent, where this is required according to national legislation, before any study related activity is carried out~3. The child has been diagnosed as having achondroplasia documented by clinical diagnosis~4. The child is between 0 years and 10 years of age, inclusive, on the date of consent / assent~5. The investigator has considered the family and prospective participating child being able to comply with the study procedures~Exclusion Criteria:~1. The child has a diagnosis of hypochondroplasia or any short stature condition other than achondroplasia (eg, spondyloepiphyseal dysplasia congenital \[SEDC\], pseudoachondroplasia, trisomy 21)~2. The child has any medical condition that may impact growth or where the treatment is known to impact growth, such as but not limited to hypothyroidism or hyperthyroidism, insulin-requiring diabetes mellitus, autoimmune inflammatory disease (including celiac disease, systemic lupus erythematosus \[SLE\], juvenile dermatomyositis, scleroderma, and others), autonomic neuropathy, or inflammatory bowel disease~3. Treatment in the previous 12 months prior to consent and assent with growth hormone, insulin-like growth factor 1 (IGF-1), anabolic steroids, or any other drug expected to affect growth velocity~4. Any surgery that affects the growth plate of the long bones that is planned, or has occurred in the past 18 months~5. Participation in any interventional study (investigational product or device) for treatment of achondroplasia or short stature~6. Has had bone-related surgery impacting assessment of anthropometric measurements or is expected to have it during the study period. Children with previous limb-lengthening surgery may enroll if surgery occurred at least 18 months prior to the date of consent/assent and healing is complete without sequelae as determined by the investigator~7. Has any condition that in the view of the investigator places the child at high risk of poor compliance with the visit schedule or of not completing the study.~8. Any concurrent disease or condition that in the view of the investigator would interfere with study participation

- Gender: ALL
- Minimum Age: 0 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Extension Study To Enroll Subjects Who Were Enrolled In B5301001 Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects previously randomized to Pfizer clinical study B5301001.~* Subjects must be able to tolerate up to a 3 hour scar revision surgery under sedation and local anesthesia.~Exclusion Criteria:~* Pregnant female subject; breastfeeding female subjects; male subjects with partners currently pregnant.~* Any previous history of intolerable adverse reactions to PF-06473871, such as serious adverse events attributed to study drug or having been withdrawn due to AE in prerequisite study B5301001.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 57 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): The number of doses each subject receives will be consistent with number received in protocol B5301001 (Group 1 = 4 doses).
- Group 2 (Type: EXPERIMENTAL): The number of doses each subject receives will be consistent with number received in protocol B5301001 (Group 2 = 3 doses).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: S0125, Chemotherapy, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Older Patients With Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Morphologically confirmed acute myeloid leukemia (AML) (within 180 days of diagnosis) OR~* Secondary AML (secondary to myelodysplastic syndromes (MDS) or to prior leukemogenic therapy)~* Must have A1 marrow, B1 blood, and C1 extramedullary disease status~* Must have received prior remission induction chemotherapy~* Must have a genotypically HLA-identical sibling donor available that is not a monozygotic identical twin~* No M3 AML or blastic transformation of chronic myelogenous leukemia~* If history of CNS leukemia, no leukemia cells in CNS by lumbar puncture within past 7 days~* Must be concurrently enrolled on protocols SWOG-9007 and SWOG-S9910~PATIENT CHARACTERISTICS:~Age~* 55 to 69~Performance status~* Zubrod 0-2~Life expectancy~* Not specified~Hematopoietic~* See Disease Characteristics~Hepatic~* Not specified~Renal~* Not specified~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* HIV negative~* No other malignancy within the past 2 years except for the following:~  * Adequately treated basal cell or squamous cell skin cancer~ * Carcinoma in situ of the cervix~ * Adequately treated stage I or II cancer in complete remission~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No prior allogeneic hematopoietic stem cell transplantation~Chemotherapy~* See Disease Characteristics~* Prior consolidation therapy allowed~Endocrine therapy~* Not specified~Radiotherapy~* Not specified~Surgery~* Prior organ transplantation allowed provided not concurrently receiving immunosuppressive therapy

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- treatment (Type: EXPERIMENTAL): patient conditioning - fludarabine 30 mg/m2 IV over 1 hour Days -4, -3, -2; TBI 6-7 cGy/min Day 0 post-transplant immunosuppression - cyclosporine 6.25 mg/kg bid PO D -3 to +180 (begin taper on D+35); mycophenolate mofetil 15mg/kg bid PO D0 to +27

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Intervene With Nutrition for Gastroparesis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Identify inclusion criteria.~* Male or female gender~* Ages 18 to 65~* Established diagnosis of gastroparesis confirmed by gastric emptying study within the last 5 years.~* No changes to gastroparesis medications in the 3 months prior to recruitment.~* Patients with hysterectomy, appendectomy, cholecystectomy and fundoplication are ok to participate.~* Able to give informed consent.~* Patient willing to supplement diet with Kate Farms~* Ability to adhere to the study visit schedule and other protocol requirements.~Identify exclusion criteria.~* Are nursing or pregnant.~* Diagnosis of mechanical small bowel obstruction within 3 months prior to recruitment~* Patients with a history of gastric surgery, including gastrectomy, small bowel resection or bariatric surgery~* The use of narcotic medications in the month prior to study enrollment or during the study period~* Diagnosis of short gut syndrome~* Allergic to any ingredients in the Kate Farms formula~* Untreated small intestinal bacterial overgrowth

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Assess Nutritional Effects of Nutritional Formula (Type: OTHER): Self-controlled study in which we will assess the nutritional effects of the Kate Farm Peptide 1.5 nutritional Formula in patients with gastroparesis, relative to their pre-enrollment nutritional formula regimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>=18 years of age~* HIV-1 infection~* Triple class treatment-experienced, Fuzeon- and integrase-inhibitor naive~* GSS \>= 3 ; nucleosides excluded~Exclusion Criteria:~* Adverse clinical or laboratory experience \>ACTG Grade 4~* Untreated infection, intercurrent illness, drug toxicity or other condition contraindicating an antiretroviral regimen~* Malignancy requiring chemotherapy or radiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase I (Type: EXPERIMENTAL): Phase 1: ENF 90mg SC BID): In the first phase or cohort phase of day I-1 through Week I-12 of the trial all patients received enfuvirtide (ENF) 90 mg subcutaneously (SC) twice daily (BID) + Isentress® \[raltegravir\] (RAL) 400-mg orally (PO) BID + optimized background (OB) with at least 1 fully active antiretroviral (ARV) agent excluding nucleoside reverse transcriptase inhibitor (NRTIs).
- Phase II (Type: EXPERIMENTAL): In the randomized comparator Phase II of the trial- (Day II-1 through Week II-16): Virologic responders confirmed HIV-1 RNA ≤50 copies/mL from Phase I were randomized to 1 of 2 treatment arms of~(Phase II Arm A: Phase I then ENF 90mg SC BID): ENF 90 mg SC BID + RAL 400 mg PO BID + OB with at least 1 fully active ARV agent excluding NRTIs or (Phase II Arm B: Phase I then ENF 180mg SC QD): ENF 180 mg SC once daily (QD) + RAL 400 mg PO BID + OB with at least 1 fully active ARV agent excluding NRTIs.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues